Clifutinib
Clifutinib is an investigational new drug that is being developed by Sunshine Lake Pharma Co., Ltd. for the treatment of acute myeloid leukaemia (AML).
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Clifutinib is an investigational new drug that is being developed by Sunshine Lake Pharma Co., Ltd. for the treatment of acute myeloid leukaemia (AML). It is a fms related receptor tyrosine kinase 3 (FLT3) inhibitor.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1365630276 under CC BY-SA 4.0; modifications have been made.